TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06445322: Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Sponsor: Ascidian Therapeutics, Inc · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 50 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,957,000

Rescue Site Savings

+$1,287,500

Unlock Full NCT06445322 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06445322 Rescue Dossier →